Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

被引：398

作者：

Gillessen, Silke ^{[1
,2
]}

Attard, Gerhardt ^{[3
]}

Beer, Tomasz M. ^{[4
]}

Beltran, Himisha ^{[5
]}

Bossi, Alberto ^{[6
]}

Bristow, Rob ^{[7
,8
]}

Carver, Brett ^{[9
]}

Castellano, Daniel ^{[10
]}

Chung, Byung Ha ^{[11
]}

Clarke, Noel ^{[12
,13
]}

Daugaard, Gedske ^{[14
]}

Davis, Ian D. ^{[15
,16
]}

de Bono, Johann ^{[3
]}

dos Reis, Rodolfo Borges ^{[17
]}

Drake, Charles G. ^{[18
]}

Eeles, Ros ^{[19
,20
]}

Efstathiou, Eleni ^{[21
]}

Evans, Christopher P. ^{[22
]}

Fanti, Stefano ^{[23
]}

Feng, Felix ^{[24
]}

Fizazi, Karim ^{[25
]}

Frydenberg, Mark ^{[26
]}

Gleave, Martin ^{[27
]}

Halabi, Susan ^{[28
]}

Heidenreich, Axel ^{[29
]}

Higano, Celestia S. ^{[30
,31
]}

James, Nicolas ^{[32
,33
]}

Kantoff, Philip ^{[34
,35
]}

Kellokumpu-Lehtinen, Pirkko-Liisa ^{[36
]}

Khauli, Raja B. ^{[37
]}

Kramer, Gero ^{[38
]}

Logothetis, Chris ^{[39
]}

Maluf, Fernando ^{[40
,41
]}

Morgans, Alicia K. ^{[42
]}

Morris, Michael J. ^{[43
]}

Mottet, Nicolas ^{[44
]}

Murthy, Vedang ^{[45
]}

Oh, William ^{[46
]}

Ost, Piet ^{[47
]}

Padhani, Anwar R. ^{[48
,49
]}

Parker, Chris ^{[50
]}

Pritchard, Colin C. ^{[51
]}

Roach, Mack ^{[24
]}

Rubin, Mark A. ^{[52
,53
]}

Ryan, Charles ^{[54
]}

Saad, Fred ^{[55
]}

Sartor, Oliver ^{[56
]}

Scher, Howard ^{[57
]}

Sella, Avishay ^{[58
]}

Shore, Neal ^{[59
]}

机构：

[1] Cantonal Hosp St Gallen, Dept Med Oncol, St Gallen, Switzerland

[2] Univ Bern, Bern, Switzerland

[3] Inst Canc Res Royal Marsden, Dept Med Oncol, London, England

[4] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[5] Weill Cornell Med, Dept Med Oncol, New York, NY USA

[6] Goustave Roussy, Prostate Brachytherapy Unit, Genito Urinary Oncol, Dept Radiat Oncol, Paris, France

[7] Princess Margaret Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada

[8] Univ Toronto, Toronto, ON, Canada

[9] Sidney Kimmel Ctr Prostate & Urol Canc, Dept Urol, New York, NY USA

[10] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain

[11] Yonsei Univ Hlth Syst, Gangnam Severance Hosp, Dept Urol, Seoul, South Korea

[12] Christie Hosp, Dept Urol, Manchester, Lancs, England

[13] Salford Royal Hosp, Dept Urol, Manchester, Lancs, England

[14] Copenhagen Univ Hosp, Rigshosp, Dept Med Oncol, Copenhagen, Denmark

[15] Monash Univ, Box Hill, Vic, Australia

[16] Eastern Hlth Clin Sch, Eastern Hlth, Box Hill, Vic, Australia

[17] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Urol, Sao Paulo, Brazil

[18] Columbia Univ, Dept Med Oncol, Div Haematol Oncol, Med Ctr, New York, NY USA

[19] Inst Canc Res, Dept Clin Oncol & Genet, London, England

[20] Royal Marsden NHS Fdn Trust, London, England

[21] Univ Texas MD Anderson Canc Ctr, Dept Med Oncol, Houston, TX 77030 USA

[22] Univ Calif Davis, Sch Med, Dept Urol, Davis, CA 95616 USA

[23] Univ Bologna, Policlin S Orsola, Dept Nucl Med, Bologna, Italy

[24] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA

[25] Univ Paris Sud, Gustave Roussy, Dept Med Oncol, Paris, France

[26] Monash Univ, Fac Med Nursing & Hlth Sci, Dept Anat & Dev Biol, Dept Surg, Clayton, Vic, Australia

[27] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol, Vancouver, BC, Canada

[28] Duke Univ, Dept Clin trials & Stat, Durham, NC USA

[29] Univ Hosp Koln, Dept Urol, Cologne, Germany

[30] Univ Washington, Div Med Oncol, Dept Med, Seattle, WA 98195 USA

[31] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[32] Queen Elizabeth Hosp, Clin Oncol, Dept Clin Oncol, Birmingham, W Midlands, England

[33] Univ Birmingham, Birmingham, W Midlands, England

[34] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, 1275 York Ave, New York, NY 10021 USA

[35] Weill Cornell Med Coll, New York, NY USA

[36] Univ Tampere, Tampere Univ Hosp, Fac Med & Life Sci, Dept Clin Oncol, Tampere, Finland

[37] Amer Univ Beirut, Med Ctr, Dept Urol, Beirut, Lebanon

[38] Med Univ Vienna, Dept Urol, Vienna, Austria

[39] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA

[40] Hosp Israelita Albert Einstein, Dept Med Oncol, Sao Paulo, Brazil

[41] Beneficencia Portuguesa Sao Paulo, Dept Med Oncol, Sao Paulo, Brazil

[42] Vanderbilt Univ, Med Ctr, Div Hematol Oncol, Dept Med Oncol & Epidemiol, Nashville, TN USA

[43] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, 1275 York Ave, New York, NY 10021 USA

[44] Univ Hosp Nord St Etienne, Dept Urol, St Etienne, France

[45] Tata Mem Hosp, Dept Radiat Oncol, Mumbai, Maharashtra, India

[46] Icahn Sch Med Mt Sinai, Dept Med Oncol, Div Hematol & Med Oncol, Tisch Canc Inst, New York, NY 10029 USA

[47] Ghent Univ Hosp, Dept Radiat Oncol, Ghent, Belgium

[48] Mt Vernon Canc Ctr, Dept Radiol, London, England

[49] Inst Canc Res, London, England

[50] Royal Marsden NHS Fdn Trust, Dept Clin Oncol, Sutton, Surrey, England

来源：

EUROPEAN UROLOGY | 2018年 / 73卷 / 02期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

Advanced and high-risk localized prostate cancer; Castration-naive and castration-resistant prostate cancer; Therapeutics; Consensus; Oligometastatic prostate cancer; ANDROGEN-DEPRIVATION THERAPY; RANDOMIZED CONTROLLED-TRIAL; LYMPH-NODE DISSECTION; BRCA2 MUTATION CARRIERS; PHASE-III TRIAL; SYMPTOMATIC SKELETAL EVENTS; METASTASIS-FREE SURVIVAL; ESTRO-SIOG GUIDELINES; OF-THE-LITERATURE; TERM-FOLLOW-UP;

D O I：

10.1016/j.eururo.2017.06.002

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Backgr(o)und: In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some of these topics. Objective: To present the report of APCCC 2017. Design, setting, and participants: Ten important areas of controversy in APC management were identified: high-risk localised and locally advanced prostate cancer; "oligometastatic'' prostate cancer; castration-naive and castration-resistant prostate cancer; the role of imaging in APC; osteoclast-targeted therapy; molecular characterisation of blood and tissue; genetic counselling/testing; side effects of systemic treatment(s); global access to prostate cancer drugs. A panel of 60 international prostate cancer experts developed the program and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 150 predefined questions, which have been developed following a modified Delphi process. Results and limitations: Voting is based on panellist opinion, and thus is not based on a standard literature review or meta-analysis. The outcomes of the voting had varying degrees of support, as reflected in the wording of this article, as well as in the detailed voting results recorded in Supplementary data. Conclusions: The presented expert voting results can be used for support in areas of management of men with APC where there is no high-level evidence, but individualised treatment decisions should as always be based on all of the data available, including disease extent and location, prior therapies regardless of type, host factors including comorbidities, as well as patient preferences, current and emerging evidence, and logistical and economic constraints. Inclusion of men with APC in clinical trials should be strongly encouraged. Importantly, APCCC 2017 again identified important areas in need of trials specifically designed to address them. Patient summary: The second Advanced Prostate Cancer Consensus Conference APCCC 2017 did provide a forum for discussion and debates on current treatment options for men with advanced prostate cancer. The aim of the conference is to bring the expertise of world experts to care givers around the world who see less patients with prostate cancer. The conference concluded with a discussion and voting of the expert panel on predefined consensus questions, targeting areas of primary clinical relevance. The results of these expert opinion votes are embedded in the clinical context of current treatment of men with advanced prostate cancer and provide a practical guide to clinicians to assist in the discussions with men with prostate cancer as part of a shared and multidisciplinary decision-making process. (C) 2017 European Association of Urology. Published by Elsevier B.V.

引用

页码：178 / 211

页数：34

共 196 条

[1] More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer [J].

Abdollah, Firas ;

Gandaglia, Giorgio ;

Suardi, Nazareno ;

Capitanio, Umberto ;

Salonia, Andrea ;

Nini, Alessandro ;

Moschini, Marco ;

Sun, Maxine ;

Karakiewicz, Pierre I. ;

Shariat, Sharhokh F. ;

Montorsi, Francesco ;

Briganti, Alberto .

EUROPEAN UROLOGY, 2015, 67 (02) :212-219

[2] Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival [J].

Abugharib, Ahmed ;

Jackson, William C. ;

Tumati, Vasu ;

Dess, Robert T. ;

Lee, Jae Y. ;

Zhao, Shuang G. ;

Soliman, Moaaz ;

Zumsteg, Zachary S. ;

Mehra, Rohit ;

Feng, Felix Y. ;

Morgan, Todd M. ;

Desai, Neil ;

Spratt, Daniel E. .

JOURNAL OF UROLOGY, 2017, 197 (03) :662-668

[3] The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer [J].

Afshar-Oromieh, Ali ;

Avtzi, Eleni ;

Giesel, Frederik L. ;

Holland-Letz, Tim ;

Linhart, Heinz G. ;

Eder, Matthias ;

Eisenhut, Michael ;

Boxler, Silvan ;

Hadaschik, Boris A. ;

Kratochwil, Clemens ;

Weichert, Wilko ;

Kopka, Klaus ;

Debus, Juergen ;

Haberkorn, Uwe .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (02) :197-209

[4] Germline genetic profiling in prostate cancer: latest developments and potential clinical applications [J].

Ahmed, Mahbubl ;

Eeles, Rosalind .

FUTURE SCIENCE OA, 2016, 2 (01)

[5] Impact of Androgen-Deprivation Therapy on Cognitive Function in Men With Nonmetastatic Prostate Cancer [J].

Alibhai, Shabbir M. H. ;

Breunis, Henriette ;

Timilshina, Narhari ;

Marzouk, Shireen ;

Stewart, Diane ;

Tannock, Ian ;

Naglie, Gary ;

Tomlinson, George ;

Fleshner, Neil ;

Krahn, Murray ;

Warde, Padraig ;

Canning, Sarah Duff .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (34) :5030-5037

[6] Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes [J].

Alibhai, Shabbir M. H. ;

Duong-Hua, Minh ;

Sutradhar, Rinku ;

Fleshner, Neil E. ;

Warde, Padraig ;

Cheung, Angela M. ;

Paszat, Lawrence F. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (21) :3452-3458

[7] Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer [J].

Annala, Matti ;

Struss, Werner J. ;

Warner, Evan W. ;

Beja, Kevin ;

Vandekerkhove, Gillian ;

Wong, Amanda ;

Khalaf, Daniel ;

Seppala, Irma-Liisa ;

So, Alan ;

Lo, Gregory ;

Aggarwal, Rahul ;

Small, Eric J. ;

Nykter, Matti ;

Gleave, Martin E. ;

Chi, Kim N. ;

Wyatt, Alexander W. .

EUROPEAN UROLOGY, 2017, 72 (01) :34-42

[8]

[Anonymous], 2016, WHO classification of tumours of the urinary system and male genital organs

[9]

[Anonymous], 2015, J NATL CANC I

[10]

[Anonymous], BJUINT2013

← 1 2 3 4 5 6 7 8 9 10 →